Key players within this competitive global market include countries from North America, Europe, Asia Pacific, Latin America, Africa and the Middle East as well as a number of pharmaceutical companies such as Alkermes Plc, Allergan, Forest Laboratories, Inc, Glaxosmithkline Plc, Mylan Laboratories, Pfizer Inc, Purdue Pharma Lp, Reckitt Benckiser Pharmaceuticals and Teva Pharmaceuticals. Each player will be working on doing what they can to make treatment options available victims of substance abuse. According to researchmarkets.com: the global substance abuse treatment market was valued at US$ 13.22 billion in 2016, and is expected to reach US$ 27.91 billion by 2025.
As stated earlier, the research is quite extensive and very much in-depth, which is most likely why it yields such a high price tag. You can read more about the study here. The intent of this blog is to provide a snapshot of what’s covered in this study and at the very least pique the interest of the reader, perhaps to garner a discussion among the community about whether or not this magnanimous undertaking will be effective. So with that in mind, here are some of the things to be covered in the research.
This study delves into the purpose of the markets, what drives them, their inner dynamics, challenges, intentions on spreading awareness and more. It also focuses on opportunities and the landscape of key players in the Substance Abuse Treatment Market along with exploring specific types of treatment for alcohol, nicotine and drug abuse. Currently, the U.S. is dominating this market, due in part to its number of those dealing with substance abuse and addiction, the high cost of therapy, and reimbursement policies. Asia stands to gain as well due to its growing economy, among other factors. Key innovation and technological advancements are being pursued, and government intervention, increases in opioid prescriptions and efforts to curb substance abuse are all driving motivators to get things moving in the right direction. Of course, all of it comes with a cost and as stated earlier, the substance abuse treatment market is building into a financial beast all its own.
Hopefully, this is something that has the potential to be effective and not just business as usual. Some would argue that Big Pharma is just making money off of the toxic market they created in the first place. Again, the truth remains to be seen. Hopefully, the world in its infinite wisdom will all do their part to come together using their dollars to make sense and perhaps make a little change in the process as well.
IPRP is motivated by seeing change in people, find out how at inprp.org.